Selected publications
- Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics. 2020 Academic Article GET IT
-
Multicenter phase II study of lurbinectedin in BRCAMutated and unselected metastatic advanced breast cancer and biomarker assessment substudy.
Journal of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 5 -
Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium trial NCT01149083.
Clinical Cancer Research.
2017
Academic Article
GET IT
Times cited: 37 -
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3.
Breast Cancer Research and Treatment.
2017
Academic Article
GET IT
Times cited: 9 -
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.
Breast Cancer Research.
2016
Academic Article
GET IT
Times cited: 13 -
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.
Nature Communications.
2016
Academic Article
GET IT
Times cited: 24 -
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.
Breast Cancer Research.
2016
Academic Article
GET IT
Times cited: 13 -
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Gynecologic Oncology.
2016
Review
GET IT
Times cited: 8 -
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.
Nature Communications.
2016
Academic Article
GET IT
Times cited: 38 -
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.
Nature Genetics.
2016
Review
GET IT
Times cited: 53 -
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.
Breast Cancer Research.
2015
Academic Article
GET IT
Times cited: 13 -
Assessing associations between the AURKAHMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.
PLoS ONE.
2015
Academic Article
GET IT
Times cited: 11 -
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
JAMA - Journal of the American Medical Association.
2015
Academic Article
GET IT
Times cited: 179 -
Breast cancer risk reduction, version 2.2015 clinical practice guidelines in oncology clinical practice guidelines in oncology.
JNCCN Journal of the National Comprehensive Cancer Network.
2015
Review
GET IT
Times cited: 22 -
Candidate genetic modifiers for breast and ovarian cancer risk inBRCA1andBRCA2 mutation carriers.
Cancer Epidemiology Biomarkers and Prevention.
2015
Academic Article
GET IT
Times cited: 14 -
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
Breast Cancer Research.
2014
Academic Article
GET IT
Times cited: 25 -
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
PLoS Genetics.
2014
Academic Article
GET IT
Times cited: 22 -
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.
Nature Genetics.
2013
Academic Article
GET IT
Times cited: 348 -
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk.
PLoS Genetics.
2013
Academic Article
GET IT
Times cited: 169 -
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007.
Breast Journal.
2009
Academic Article
GET IT
Times cited: 25 -
Proceedings of the International Consensus Conference on Breast Cancer Risk, Genetics, & Risk Management, April, 2007.
Cancer.
2008
Conference Paper
GET IT
Times cited: 68 -
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.
Clinical Cancer Research.
2006
Academic Article
GET IT
Times cited: 21